Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Crinetics Pharmaceuticals Inc (NQ: CRNX ) 45.58 +1.37 (+3.10%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,277,293 Open 44.25 Bid (Size) 43.96 (1) Ask (Size) 48.18 (1) Prev. Close 44.21 Today's Range 43.76 - 46.16 52wk Range 15.76 - 53.70 Shares Outstanding 54,026,103 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner June 18, 2024 Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 10, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Performance YTD +28.79% +28.79% 1 Month -9.81% -9.81% 3 Month +2.91% +2.91% 6 Month +26.93% +26.93% 1 Year +145.19% +145.19% More News Read More Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday June 04, 2024 Via Benzinga 17 Analysts Have This To Say About Crinetics Pharmaceuticals June 04, 2024 Via Benzinga 18 Analysts Have This To Say About Crinetics Pharmaceuticals May 14, 2024 Via Benzinga Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS) June 03, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly June 03, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs May 30, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday May 22, 2024 Via Benzinga Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts May 22, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 10, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024 May 08, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 May 02, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 11, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why March 19, 2024 Via Benzinga Exposures Product Safety Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) Leading the Way in Tuesday Trading Based on Percentage Gain March 19, 2024 Via Investor Brand Network National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday March 19, 2024 Via Benzinga Topics Stocks Exposures US Equities Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session March 19, 2024 Via Benzinga Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win March 19, 2024 Via Investor's Business Daily Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients March 19, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome March 12, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 11, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday March 01, 2024 Via Benzinga Topics Stocks Exposures US Equities Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.